RayKnowChina Research Map
Shortlist

Changsha

Hunan Provincal Tumor Hospital

Listed for 1 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Hunan Provincal Tumor Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Lung cancer肺癌0 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Pancreatic cancer, Breast cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Lung cancer

肺癌

Led no English-language PubMed papers on lung cancer in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

6 hospitals in Changsha for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT06706219

    Age 18 years to 70 years (registered criteria)

    Led by Hunan Cancer Hospital; 1 listed hospital as study siteChangsha

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

All its trials on ClinicalTrials.gov, any status13
  1. Trial of Tumor Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With Lung CancerStatus unknownNCT03807102Lead (inferred)Phase 1/Phase 2Start 2024-01
  2. Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLCCompletedNCT04144608Lead (inferred)Phase 2Start 2020-01
  3. PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLCStatus unknownNCT04144569Lead (inferred)Phase 2Start 2019-01
  4. Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung CancerCompletedNCT04144582Lead (inferred)Phase 2Start 2019-01
  5. Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung CancerCompletedNCT03652857Lead (inferred)Phase 2Start 2017-01
  6. Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung CancerStatus unknownNCT03198923Lead (inferred)Phase 1Start 2017-09
  7. Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLCNot yet recruitingNCT06706219Study sitePhase 2Start 2026-05
  8. The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung CancerCompletedNCT06477055Study siteStart 2025-12
  9. Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS StudyCompletedNCT03798743Study sitePhase 2Start 2019-01
  10. Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung CancerStatus unknownNCT03647592Study siteStart 2018-06
  11. Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung CancerCompletedNCT01980212Study siteStart 2013-05
  12. Correlation Research of Thioredoxin Reductase in Lung CancerCompletedNCT01985113Study siteStart 2013-05
  13. Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)CompletedNCT01991418Study siteStart 2013-05

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

Hunan Provincal Tumor Hospital

长沙

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

No hospital-level ROR record matched.

Suggest a correctionDownload the data